Table 2.
Antiviral treatment of HCV-associated GN: clinical studies.
| Authors | SVR | Antiviral therapy, schedule | Reference year |
|---|---|---|---|
| Mazzaro et al. [75] | 14% (1/7) | Lymphoblastoid-IFN | 2000 |
| Bruchfeld et al. [76] | 71% (5/7) | IFN-α-2b + ribavirin (n = 5) | 2003 |
| Peg-FN-α-2b + ribavirin (n = 2) | |||
| Rossi et al. [79] | 100% (3/3) | IFN-α-2b + ribavirin | 2003 |
| Alric et al. [26] | 67% (12/18) | IFN-α + ribavirin (n = 14) | 2004 |
| Peg-FN-α + ribavirin (n = 4) | |||
| Saadoun et al. [80] | 59% (13/22) | IFN-α-2b + ribavirin (n = 12) | 2006 |
| Peg-FN-α-2b + ribavirin (n = 10) | |||
| Roccatello et al. [70] | 11% (6/55) | IFN (n = 10) | 2007 |
| IFN + ribavirin (n = 45) | |||
| Garini et al. [77] | 75% (3/4) | IFN-α + ribavirin (n = 2) | 2007 |
| Peg-FN-α-2a + ribavirin (n = 2) | |||
| Abbas et al. [78] | 13% (4/30) | IFN-α + ribavirin | 2008 |
| Saadoun et al. [84] | 40% (4/10) | Peg-IFN-α-2b + ribavirin | 2010 |
| Fabrizi et al. | 0.42 (95% CI, 0.24; 0.61) | Pooled analysis | 2012 |
Results have been calculated according to an intention-to-treat (ITT) analysis.
SVR: sustained virological response.